All TNF Tumor necrosis factor antibodies

Tumor necrosis factor (TNF) is a cytokine that plays a crucial role in the regulation of immune cells and inflammation. TNF is produced by macrophages, T cells, and other immune cells in response to infection, injury, or inflammation. TNF is involved in the pathogenesis of several autoimmune diseases such as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD).
TNF inhibitors are a class of drugs that target TNF and are used to treat autoimmune diseases. They work by blocking the action of TNF and reducing inflammation. TNF inhibitors are used to treat RA, psoriasis, psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn's disease, and ulcerative colitis.
There are several types of TNF inhibitors available on the market. These include adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), golimumab (Simponi), and certolizumab pegol (Cimzia).
Adalimumab is a fully human monoclonal antibody that binds to TNF-alpha and blocks its interaction with cell surface receptors. Etanercept is a fusion protein that binds to TNF-alpha and prevents it from binding to its receptors. Infliximab is a chimeric monoclonal antibody that binds to both soluble and transmembrane forms of TNF-alpha. Golimumab is a human monoclonal antibody that binds to TNF-alpha and blocks its interaction with cell surface receptors. Certolizumab pegol is a PEGylated Fab fragment of a humanized monoclonal antibody that binds to TNF-alpha.

Showing 1 - 24 of 6361 results